Outcomes of systemic treatment in advanced melanoma after progression on anti–PD-1 therapy: a real-world study with literature review

INTRODUCTION: Currently, a substantial proportion of patients are still treated with first-line anti-PD-1 immunotherapy (ICI). After disease progression, treatment options, especially for patients with BRAF-negative tumors, are limited. One regimen used in real-world practice in this setting is ipil...

Descripció completa

Dades bibliogràfiques

Autors principals:	Piotr J. Błoński, Krzysztof Ostaszewski, Barbara Buchalska, Julia Szymkiewicz, Tomasz Switaj, Paweł Rogala, Katarzyna Kozak, Monika Dudzisz-Śledź, Anna M. Czarnecka
Format:	Artigo
Idioma:	Inglês
Publicat:	Via Medica 2026-04-01
Col·lecció:	Oncology in Clinical Practice
Matèries:	ipilimumab melanoma immunotherapy immune checkpoint inhibitors anti-CTLA-4
Accés en línia:	https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/111553
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!